InnoCan Pharma Corporation

INNO

CA45783P1027

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 02:41:15 2025-01-20 pm EST			5-day change	1st Jan Change
0.1650 ^CAD	0.00%		-8.33%	-21.43%

Dec. 31	Innocan Pharma Closes Private Placement for $635,444	MT
Dec. 30	InnoCan Pharma Corporation announced that it has received CAD 0.635445 million in funding	CI

Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million

May 27, 2024 at 04:46 pm EDT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about InnoCan Pharma Corporation

Innocan Pharma Closes Private Placement for $635,444	Dec. 31	MT
InnoCan Pharma Corporation announced that it has received CAD 0.635445 million in funding	Dec. 30	CI
InnoCan Pharma Corporation announced that it expects to receive CAD 0.7 million in funding	Dec. 18	CI
Innocan Pharma's Annual Update Touts Advancement of LPT-CBD Development	Dec. 12	MT
InnoCan Pharma Releases Encouraging Results from Study of LPT-CBD on Minipigs	Nov. 26	MT
Innocan Pharma Corporation Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs	Nov. 26	CI
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 20	CI
InnoCan Pharma Swings to a Q3 Profit on Revenue Gains	Nov. 20	MT
Innocan Pharma's LPT-CBD Shows Success in Relieving Osteoarthritis Pain in Dogs	24-10-11	MT
Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs	24-10-11	CI
Innocan Says FDA "Positive" on it Liposomal Technology-CBD Drug	24-09-03	MT
Innocan Pharma Corporation Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting	24-09-03	CI
InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding	24-08-28	CI
InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding	24-08-21	CI
InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-12	CI
Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center	24-07-26	MT
Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center	24-07-26	CI
Innocan Pharma Engages Pain-Management Expert Ahead of FDA Meeting	24-07-02	MT
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs	24-06-11	MT
InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-27	CI
Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million	24-05-27	MT
Refile: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	24-05-21	MT
InnoCan Pharma Brief: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain	24-05-21	MT
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey	24-05-09	CI
InnoCan Pharma Corporation Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain	24-04-22	CI

Chart InnoCan Pharma Corporation

Duration

Period

INNO: Dynamic Chart

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

Employees

Sector

Pharmaceuticals

Calendar

2025-03-26 - Q4 2024 Earnings Release (Projected)

More about the company